Copy the page URI to the clipboard
Hawkes, Cheryl A.; Ng, Vivian and McLaurin, JoAnne
(2009).
DOI: https://doi.org/10.1002/ddr.20290
Abstract
Alzheimer disease (AD) is characterized pathologically by extracellular amyloid deposits composed of Aβ peptide, neurofibrillary tangles (NFTs) made up of hyperphosphorylated tau, and a deficit of cholinergic neurons in the basal forebrain. Presently, only symptomatic therapies are available for the treatment of AD and these therapies have a limited time frame of utility. Amyloid disorders represent the effects of chronic Aβ production and are not a secondary pathological effect caused by a distant trigger; therefore targeting Aβ is a viable pursuit. In this review, we will discuss the various small molecule anti-aggregation inhibitors that have been reported in the literature, with emphasis on compounds that are presently being investigated in clinical trials.
Viewing alternatives
Download history
Metrics
Public Attention
Altmetrics from AltmetricNumber of Citations
Citations from DimensionsItem Actions
Export
About
- Item ORO ID
- 44095
- Item Type
- Journal Item
- ISSN
- 1098-2299
- Extra Information
- Special Issue: Alzheimer's Disease: A Light at the End of the Tunnel?
- Keywords
- amyloid; aggregation; inhibitors; Alzheimer's disease
- Academic Unit or School
-
Faculty of Science, Technology, Engineering and Mathematics (STEM) > Life, Health and Chemical Sciences
Faculty of Science, Technology, Engineering and Mathematics (STEM) - Copyright Holders
- © 2009 Wiley-Liss, Inc.
- Related URLs
- Depositing User
- Cheryl Hawkes